Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

Brief Summary

The purpose of this study is to examine the effect of a low-dose ketamine infusion on depression symptoms within the Emergency Department (ED) visit, and healthcare utilization after leaving the ED, when administered in the ED for depression or suicidal ideation.

Intervention / Treatment

  • Drug: Ketamine
  • Drug: Sodium Chloride 0.9%

Condition or Disease

  • Depression
  • Depression Severe
  • Depression Acute
  • Depression and Suicide
  • Suicidal Ideation

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 18 Years and older   (Adult, Older Adult)
Enrollment: 29 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Oct 18, 2019
Primary Completion: May 31, 2020
Completion Date: May 31, 2020
Study First Posted: Feb 12, 2020
Results First Posted: Aug 31, 2020
Last Updated: Sep 01, 2020

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Patients will be identified based on either a chief complaint of suicidal ideation, suicide attempt, or severe depression, or if the patient indicates during intake assessment that they have thoughts of harming or killing their self. Identified patients will be assessed by the ED provider for inclusion and exclusion criteria. If the patient is a candidate for the trial and gives their informed consent for enrollment, they will be randomized to receive either ketamine or placebo by a computer program that maintains blinding. The patient will be assessed by psychiatry for disposition and treatment plan prior to receiving the study drug, and will be reassessed four hours after the infusion. Thirty days after the patient leaves the hospital (either leaves from the ED or is discharged from inpatient admission), they will be contacted to follow up on their healthcare utilization after discharge.

Eligibility Criteria

Sex: All
Minimum Age: 18

More Details

NCT Number: NCT04266288
Other IDs: MMC2019-46
Study URL: https://ClinicalTrials.gov/show/NCT04266288
Last updated: Jun 17, 2022